Why we’re expanding and investing in our research and discovery efforts
Our commitment to innovation helps ensure a brighter future for patients everywhere
June 9, 2022
We follow the science where we can make the greatest difference, now and in the future.
It’s a key component of our drive to be the premier, research-intensive biopharmaceutical company, bringing creative minds together to transform world-class science into life-changing medicines and vaccines. To realize that future, we’re making significant investments in our research and discovery facilities and infrastructure in the U.S. and around the world.
“With new facilities and capabilities, we’re carrying forward MSD’s long tradition of using the power of leading-edge science to save and improve lives,” said Rob Davis, CEO and president. “It’s a legacy of scientific excellence that has brought forward medicines and vaccines that have helped change standards of care in human and animal health.”
These efforts include the recent expansion of our Exploratory Science Center in Cambridge, Mass., a state-of-the-art home for experts in biochemistry and those who take an interdisciplinary approach to innovation. The newly expanded space opens the door to hire about 100 more scientists to help drive our discovery.
Tom McCubbins, SVP, operations, and Mike Kress, SVP, chemistry, cut the ribbon to unveil the new West Point, Pa., site expansion
Rob Davis and Fiona Marshall tour the new facilities at the Exploratory Science Center in Cambridge, Mass.
In the U.K., we’re moving ahead with plans for our 220,000-square-foot London Discovery Center. Once completed, the state-of-the-art discovery facility will accommodate about 800 employees across discovery, research, clinical and support roles, including marketing, finance and administration.
“MSD is proud to be delivering on our U.K. investment plans, with a future that puts our scientists at the heart of a vibrant center for innovation and technology development alongside leading research institutes which include some of our current research collaboration partners,” says Fiona Marshall, senior vice president of discovery, preclinical and translational medicine.
And in Pennsylvania, we’ve recently unveiled expansions to our West Point site, with a new modular lab space to facilitate process development and knowledge build between divisions. The new facility also allows for more innovation and optimization across the commercialization space.
“The world is waiting for the next big thing — innovations that will help confront the tremendous burden of disease for patients. Addressing those diseases requires the kind of world-class, scientific exploration that we are pursuing.”
- Rob Davis